Results 201 to 210 of about 78,567 (340)

Development of DNA Aptamers Against <i>Leishmania infantum</i> GP63 Protein for Therapeutic and Diagnostic Applications. [PDF]

Pharmaceutics
Román-Álamo L, Currea-Ayala D, Oliveira GS, Fallica AN, Mooren T, Avalos-Padilla Y, Fernàndez-Busquets X.   +6 more
europepmc   +1 more source

DNA Aptamer Based Nanodrugs: Molecular Engineering for Efficiency

, 2015
Sena Cansız, Liqin Zhang, Cuichen Wu, Yuan Wu, I‐Ting Teng, Weijia Hou, Yanyue Wang, Shuo Wan, Ren Cai, Jin Chen, Qiaoling Liu, Weihong Tan   +11 more
openalex   +2 more sources

Correction to “Precise Sizing and Collision Detection of Functional Nanoparticles by Deep Learning Empowered Plasmonic Microscopy”

Advanced Science, EarlyView.
wiley   +1 more source

Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial

Arthritis &Rheumatology, EarlyView.
Objective Our study objective was to identify serum protein signatures associated with progression to rheumatoid arthritis (RA) and response to abatacept in at‐risk individuals. Methods A total of 440 serum samples from 118 APIPPRA (Arthritis Prevention In the Preclinical Phase of RA with Abatacept) study participants were selected from baseline to RA ...
Marianna Jasenecova, Carl Coyle, Alina Mihalovits, Sarah Ryan, Elizabeth Pook, Esperanza Perucha, Gabrielle Harker, Melody Chin, Sam Norton, Andrew P. Cope   +9 more
wiley   +1 more source

In silico conversion of ssRNA aptamers to ssDNA: molecular dynamics assessment of structural stability and conformational preservation. [PDF]

J Comput Aided Mol Des
Lorenti S, Alqualo NO, Moreira DC, Junior NN, Goulart VA.   +4 more
europepmc   +1 more source

Multi‐Omic Profiling Reveals Immune Cell Priming Signature Linked to Lupus Prognosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is a multiorgan disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith, Dominic Sinibaldi, Saifur Rahman, Chia‐Chien Chiang, Anna M. Hansen, Jill Henault, Carlos P. Roca, Shu Wang, Kamelia Zerrouki, Rebecca Filippi, Christopher Groves, Zerai Manna, Jun Chu, Michael Davis, Sarthak Gupta, Christopher Morehouse, Melissa de los Reyes, Rachel Ettinger, Roland Kolbeck, Mariana J. Kaplan, Miguel A. Sanjuan, Richard M. Siegel, Sarfaraz A. Hasni, Kerry A. Casey   +23 more
wiley   +1 more source

A general strategy to enhance aptamer affinity by suppressing dissociation through symmetric assembly. [PDF]

Nucleic Acids Res
Zhang Z, Tian W, Gu J, Li J, Liu M, Soleymani L, Li Y.   +6 more
europepmc   +1 more source

Response Elements Based In-Silico Approach to Design RNA Aptamer Against DNA Binding Domain of a Nuclear Receptor, Special Reference to Glucocorticoid Receptor

, 2020
Thirukumaran Kandasamy, Babu Sudhamalla, Debdut Naskar   +2 more
openalex   +1 more source

Study of Aptamer-Attached Juglone in Different pH Ranges and Ionic Concentrations of Buffers [PDF]

, 2012
Hossein Hamzeiy, Mehdi Saberian, Davoud Asgaria, Yadollah Omidi   +3 more
openalex  

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source